Graham Capital Management L.P. Boosts Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Graham Capital Management L.P. boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 37.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 59,129 shares of the biopharmaceutical company's stock after acquiring an additional 16,128 shares during the quarter. Graham Capital Management L.P. owned about 0.06% of Ultragenyx Pharmaceutical worth $2,488,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 493 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth about $35,000. Human Investing LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at about $42,000. Van ECK Associates Corp lifted its holdings in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after buying an additional 273 shares during the period. Finally, Quarry LP acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at about $84,000. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 1.9%

NASDAQ:RARE traded down $0.68 during trading hours on Wednesday, hitting $34.72. 580,960 shares of the stock were exchanged, compared to its average volume of 829,357. Ultragenyx Pharmaceutical Inc. has a 52-week low of $29.59 and a 52-week high of $60.37. The firm's fifty day moving average price is $36.50 and its 200 day moving average price is $42.02. The company has a market cap of $3.28 billion, a P/E ratio of -5.48 and a beta of 0.34.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The business had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm's revenue was up 28.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.03) EPS. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on RARE shares. HC Wainwright reissued a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. JPMorgan Chase & Co. boosted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Canaccord Genuity Group boosted their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. Cantor Fitzgerald restated an "overweight" rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Finally, Piper Sandler cut their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and an average target price of $90.93.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Thomas Richard Kassberg sold 6,028 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $253,778.80. Following the completion of the sale, the executive vice president now owns 265,238 shares in the company, valued at $11,166,519.80. This trade represents a 2.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emil D. Kakkis sold 25,000 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the sale, the chief executive officer now owns 2,158,985 shares of the company's stock, valued at $91,713,682.80. This represents a 1.14% decrease in their position. The disclosure for this sale can be found here. Insiders sold 125,405 shares of company stock worth $5,285,169 in the last 90 days. Insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.